What is Beta Bionics?
Headquartered in Massachusetts and California, Beta Bionics is a Certified B Corporation dedicated to transforming the lives of children and adults living with diabetes. The company's flagship product, the iLet Bionic Pancreas System, represents a significant leap in medical technology. By integrating continuous glucose monitoring with sophisticated, self-learning control algorithms, the system mimics the body's natural physiological response to maintain tight glycemic control. This approach not only simplifies diabetes management but also addresses the broader challenges of glycemic dysregulation, positioning the company as a leader in the medtech sector.
How much funding has Beta Bionics raised?
Beta Bionics has raised a total of $495.6M across 7 funding rounds:
Angel/Seed
$1M
Private Equity
$2.5M
Series B
$63M
Series C
$57M
Series D
$100M
Series E
$60M
Stock Offering
$212.1M
Angel/Seed (2016): $1M, investors not publicly disclosed
Private Equity (2017): $2.5M, investors not publicly disclosed
Series B (2019): $63M supported by RTW Investments, LifeSci Venture Partners, Zealand Pharma A/S, Dexcom, and ArrowMark Partners
Series C (2022): $57M featuring Novo Nordisk, Eventide Asset Management, Perceptive Advisors, Farallon, RTW Investments, LifeSci Venture Partners, Soleus Capital, Pura Vida Investments, and ArrowMark Partners
Series D (2023): $100M backed by OMEGA Funds Investment, Sands Capital, and Marshall Wace
Series E (2024): $60M with participation from Wellington Management and Eventide Asset Management
Stock Issuance/Offering (2025): $212.1M, investors not publicly disclosed
Key Investors in Beta Bionics
Wellington Management
A global, independent investment management firm based in Boston, providing institutional clients with tailored investment solutions across equities and alternative strategies.
Eventide Asset Management
An investment firm that emphasizes a values-based approach, focusing on mutual funds that pursue integrity and impact across healthcare and technology sectors.
OMEGA Funds Investment
A regulated EU investment firm offering specialized financial services and access to international markets for institutional and professional clients.
What's next for Beta Bionics?
With the successful closure of this latest funding round, Beta Bionics is poised to enter a new phase of operational expansion. The strategic focus will likely center on scaling the manufacturing and distribution of the iLet system to meet growing clinical demand. Furthermore, the company is expected to continue its research and development efforts, refining its autonomous dosing technology to improve patient outcomes. As a public benefit corporation, Beta Bionics remains committed to balancing its commercial objectives with its core mission of enhancing the quality of life for the diabetes community, ensuring that its technological advancements remain accessible and impactful.
See full Beta Bionics company page
